The most common error in rash assessment is naming the diagnosis before completing the description. Morphology, distribution, blanching, evolution, and host context come first. The diagnosis follows — not the other way around.
CLINICAL PRINTABLE
Coming Soon.
Coming Soon. A one-page Rash First-Pass Assessment clinical reference is on the way.
1 · Interpretation Framework
- Primary lesion morphology is the foundation: macule (flat color change), papule (raised, solid, <1 cm), plaque (raised, solid, >1 cm), vesicle (fluid-filled, <1 cm), bulla (fluid-filled, >1 cm), pustule (pus-filled), nodule (deep solid, >1 cm), wheal (transient raised edema).
- Secondary changes describe what happened to the primary lesion: scale (dried surface cells), crust (dried exudate), erosion (superficial epithelial loss), ulcer (full-thickness skin loss), lichenification (thickened skin from chronic rubbing), excoriation (scratch marks).
- Distribution is as diagnostically important as morphology: sun-exposed vs. covered areas, flexural vs. extensor surfaces, dermatomal, centripetal vs. centrifugal, palms and soles involvement, mucous membrane involvement.
- Evolution and timeline: acute onset (hours) vs. subacute (days) vs. chronic (weeks/months). Is it spreading, stable, or resolving? Did it start somewhere specific and spread outward?
- Associated symptoms: pruritus (allergic, atopic, contact), pain or burning (HSV, shingles, cellulitis), fever (viral exanthem, drug reaction, systemic infection), systemic symptoms (lymphadenopathy, arthralgia, mucosal involvement).
- Host context: age, immune status, medications (especially new ones in the past 4–6 weeks), exposures (plants, animals, occupational, travel), personal/family history of atopy, prior similar episodes.
2 · Nuance That Changes Interpretation
Blanching vs. nonblanching
Press a glass or finger firmly against the rash. Blanching (color disappears with pressure) indicates vascular dilation — inflammatory or reactive. Nonblanching indicates extravasated red blood cells in the dermis — petechiae, purpura, or vasculitis. Nonblanching rash changes urgency immediately.
Palms, soles, and mucous membranes
Involvement of palms and soles narrows the differential significantly: secondary syphilis, Rocky Mountain spotted fever, hand-foot-mouth disease, erythema multiforme. Mucous membrane involvement (oral, genital) suggests Stevens-Johnson syndrome, erythema multiforme, pemphigus, or Behçet's disease.
Dermatomal distribution
A unilateral vesicular rash following a dermatome is shingles until proven otherwise. Do not wait for the classic presentation — prodromal pain before visible lesions is common and the diagnosis should be considered in any patient with unilateral dermatomal pain or paresthesia.
The medication timeline
Drug eruptions can occur days to weeks after starting a new medication. The most common culprits: antibiotics (especially penicillins, sulfonamides), anticonvulsants, allopurinol, NSAIDs. Always ask about medications started in the past 4–6 weeks — not just the past few days.
Immunocompromised hosts
Rashes in immunocompromised patients (HIV, transplant, chemotherapy, high-dose steroids) require a lower threshold for systemic workup and broader differential. Opportunistic infections (disseminated fungal, atypical mycobacterial, CMV) can present with skin findings that would be rare in immunocompetent hosts.
3 · What Should Raise Concern
- Nonblanching petechiae or purpura — especially with fever, headache, or neck stiffness. Meningococcemia and other bacteremic states require immediate evaluation.
- Skin sloughing, blistering, or mucosal involvement with a new medication — Stevens-Johnson syndrome / toxic epidermal necrolysis. Stop the offending drug immediately and escalate.
- Rapidly spreading erythema with warmth, pain, and systemic signs (fever, tachycardia) — necrotizing fasciitis must be excluded. Surgical consultation is urgent.
- Urticaria with throat tightness, stridor, hypotension, or syncope — anaphylaxis. Epinephrine is the first-line treatment.
- Vesicular rash in an immunocompromised patient — disseminated VZV or HSV can be life-threatening and requires urgent antiviral therapy.
4 · What Do I Do Next?
- Complete the description before naming the diagnosis: morphology, secondary changes, distribution, evolution, associated symptoms, and host context.
- Blanch test every rash — nonblanching changes the urgency and differential immediately.
- Review the medication list for anything started in the past 4–6 weeks — drug eruption is common and reversible.
- Assess for systemic involvement: fever, lymphadenopathy, mucosal lesions, joint symptoms, hemodynamic instability.
- Photograph the rash when possible — evolution over time is diagnostically valuable and photos allow comparison.
Apply It · Patient Cases
CASE 1
A 28-year-old presents with a pruritic rash on both forearms after gardening. Examination shows erythematous papules and vesicles in a linear distribution on sun-exposed forearms. The linear pattern and exposure history are consistent with contact dermatitis from a plant (likely poison ivy). The distribution tells the story before the diagnosis is named.
CASE 2
A 19-year-old presents with fever and a rash that started on the trunk and spread to the extremities. The rash is maculopapular, blanching, and spares the palms and soles. Viral exanthem is the leading diagnosis. The centripetal-to-centrifugal spread and viral prodrome support this.
NOW CHANGE ONE DETAIL
Same patient as Case 2, but the rash is nonblanching and includes petechiae on the lower extremities. The differential immediately shifts to meningococcemia, Rocky Mountain spotted fever, or vasculitis. Urgent evaluation is required — this is no longer a reassuring viral exanthem.
Bottom Line
Describe the rash completely before naming it. Morphology, distribution, blanching, evolution, and host context together produce the diagnosis — not the first pattern that comes to mind.
EVIDENCE & REFERENCES
- Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 6th ed. Elsevier; 2016. https://www.elsevier.com/books/clinical-dermatology/habif/978-0-323-26607-5
- Wolff K, Johnson RA, Saavedra AP. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 7th ed. McGraw-Hill; 2013. https://accessmedicine.mhmedical.com/book.aspx?bookid=682
- Rosenbach M, et al. Approach to the patient with a rash. In: UpToDate. Wolters Kluwer; 2024. https://www.uptodate.com